Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT/CT Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-ZHER2:4107
NCT07292571Phase 2Enrolling by invitation
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of [99mTc]Tc-ZHER2:4107 in breast cancer, sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Started Oct 2025; status: enrolling by invitation.
02
Drugs
[99mTc]Tc-ZHER2:4107
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07292571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292571.